Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, the trial has also come ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback